Issue Highlights

The development of effective endoscopic eradication therapy (EET) has changed the treatment paradigm for Barret’s Esophagus.1,2 The risk of recurrence after EET and the optimal surveillance strategy remains a topic of ongoing investigation. In this issue of Clinical Gastroenterology and Hepatology, Wani and colleagues3 address these important questions in a cohort of patients enrolled in a prospective, multicenter registry of patients with Barrett’s undergoing EET. From this registry, 807 patients who achieved complete eradication of intestinal metaplasia were included in this analysis.